OSLO, Norway, June 28, 2021 /PRNewswire/ -- Targovax
ASA, today announces that Victor
Levitsky, Chief Scientific Officer of Targovax, is invited
to present at the 4th Annual Next Gen Immuno-Oncology Virtual
Congress-US Edition.
4th Annual Next Gen Immuno-Oncology Virtual Congress-US
Edition, virtual
Date: 29 June 2021
Presenter: Victor Levitsky (CSO)
Time: 14:15 EDT / 20:15 CET
Title: Clinical efficacy and immuno-modulatory properties of
oncolytic adenovirus ONCOS-102
CONTACT:
For further information, please
contact:
Oystein Soug,
CEO
Phone: +47 906 56 525
Email: oystein.soug@targovax.com
Renate Birkeli, Investor
Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media enquires:
Andreas
Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
IR enquires:
Kim Sutton
Golodetz - LHA Investor Relations (US)
Email: kgolodetz@lhai.com
Phone: +1 212-838-3777
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/targovax/r/targovax-to-present-at-the-4th-annual-next-gen-immuno-oncology-virtual-congress-us-edition,c3375255
View original
content:https://www.prnewswire.com/news-releases/targovax-to-present-at-the-4th-annual-next-gen-immuno-oncology-virtual-congress-us-edition-301320771.html
SOURCE Targovax